Latham & Watkins has advised Octopus Ventures and Northern Gritstone as lead investors on the £5.6 million Series Seed funding round of Pencil Biosciences, a biotech company developing a full synthetic gene modulation and editing platform. The technology will impact a wide range of applications, including new therapeutic options for patients with rare diseases and cancer.
The round was led by Octopus Ventures and Northern Gritstone, with participation from Martlet Capital and existing investors including GMC Life Sciences Fund, UKI2S, and o2h Ventures.
The Latham team was led by London corporate partner Shing Lo, with associates Samantha Peacock and Venice Ma.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
